Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities

About this update from Defence Therapeutics Inc Class A

Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the expansion of internal capabilities to execute critical stages of its ACCUM®-enabled Antibody Drug Conjugates ("ADC") development pipeline. The Company has strengthened its purification, analytical characterization, conjugation development, and quality control ("QC") capabilities, while enhancing cellular testing and potency evaluation workflows within a more structured stage-gated framework to better support the advancement of its ADC partnership programs."By strengthening our internal QC, analytical, and conjugation capabilities, Defence is positioning itself to become a leading authority in the development and controlled manufacture of ACCUM®-enabled ADCs," said Mark Lambermon, PhD, Head of Quality & Operations at Defence Therapeutics. "Our focus is to establish robust, reproducible, and quality-driven processes that support the consistent generation of high-quality ACCUM®-ADC candidates for our partnership programs."To support the development of high-quality ACCUM®-enabled ADC candidates, the Company has acquired an FPLC system to improve purification workflows and the consistency of conjugated materials, while also advancing the evaluation of multiple conjugation methods, including site specific strategies. These efforts are guided by a structured framework designed to identify the most suitable conjugation approach for each partner ADC based on format, chemistry compatibility, Drug-to-Antibody Ratio ("DAR") profile, and developability characteristics such as stability and aggregation.In parallel, Defence Therapeutics is enhancing its analytical characterization and QC infrastructure through standardized analytical checkpoints, documentation practices, and reproducibility-focused processes designed to support reliable decision-making and partner-ready execution.The Company has also expanded its cellular testing capabilities with the addition of an Incucyte live-cell imaging platform designed to generate kinetic potency and mechanism-relevant cellular data designed to better assess the internalization, intracellular delivery, and cellular potency of ACCUM®-enabled ADC candidates. These capabilities...

View stock analysis, news, and events for Defence Therapeutics Inc Class A